2018.08.08
I-Mab Biopharma and MorphoSys Announce China IND Submission of TJ202/MOR202
Aug 8, 2018, I-Mab Biopharma (“I-Mab”), a Shanghai-based biotech company focused on innovative biologics in oncology and autoimmune disease, and German biopharma company MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) announced today that I-Mab has Submitted an investigational n...